Drug Profile
Research programme: infectious disease therapeutics - Elusys Therapeutics/AstraZeneca
Alternative Names: Anti Candida HP MAb; Anti Staph HP MAb; Candida HP antibody; Staph (non MRSA) HP antibodyLatest Information Update: 22 Apr 2022
Price :
$50
*
At a glance
- Originator Elusys Therapeutics; MedImmune
- Developer AstraZeneca; Elusys Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Candidiasis; Staphylococcal infections
Most Recent Events
- 20 Apr 2022 EluSys Therapeutics has been acquired by Heat Biologics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Candidiasis in USA (Parenteral, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Staphylococcal-infections in USA (Parenteral, Injection)